Paul Brennan, biopharmaceutical veteran, set to lead Microbio Ltd, developer of rapid sepsis detection tech.

Microbio Ltd, an Australian diagnostics firm, has appointed Paul Brennan as its new Board Chair on December 2, 2024. Brennan, with over 35 years of biopharmaceutical experience, is currently Immuron's non-executive chair. Microbio is focusing on its InfectID™ BSI product, which detects 26 pathogens linked to over 94% of sepsis cases in under three hours, aiming to become the standard for sepsis detection.

November 29, 2024
3 Articles

Further Reading